Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4509
Abstract: 4509Background: Pegilodecakin (PEGylated hIL-10, AM0010) alone produced 25% partial responses (PR) in heavily pre-treated (median prior therapies 3) RCC pts. IL-10 receptors and PD1 are expressed on activated and exhausted CD8+ T cells. IL-10 stimulates… read more here.
Keywords: pembro; rcc; pegilodecakin nivo; pegilodecakin nivolumab ... See more keywords